Intuitive Surgical, Inc. (NASDAQ:ISRG) Receives $613.10 Consensus Target Price from Analysts

Shares of Intuitive Surgical, Inc. (NASDAQ:ISRG) have been given a consensus rating of “Moderate Buy” by the twenty-one brokerages that are covering the stock, MarketBeat.com reports. One analyst has rated the stock with a sell rating, four have assigned a hold rating and sixteen have assigned a buy rating to the company. The average 1-year price target among brokerages that have updated their coverage on the stock in the last year is $613.10.

A number of brokerages have commented on ISRG. CICC Research initiated coverage on Intuitive Surgical in a report on Monday, January 27th. They set a “neutral” rating and a $550.00 target price for the company. Royal Bank of Canada increased their price objective on Intuitive Surgical from $611.00 to $641.00 in a research note on Monday, January 27th. Erste Group Bank raised shares of Intuitive Surgical from a “hold” rating to a “buy” rating in a research note on Tuesday, November 19th. BTIG Research upped their target price on shares of Intuitive Surgical from $535.00 to $561.00 and gave the stock a “buy” rating in a report on Tuesday, November 26th. Finally, Jefferies Financial Group raised their price target on shares of Intuitive Surgical from $475.00 to $575.00 in a research note on Monday, January 27th.

Intuitive Surgical Stock Down 2.9 %

ISRG stock opened at $573.74 on Friday. The stock has a market capitalization of $204.35 billion, a P/E ratio of 89.51, a P/E/G ratio of 5.85 and a beta of 1.39. Intuitive Surgical has a 52 week low of $364.17 and a 52 week high of $616.00. The firm has a 50-day simple moving average of $567.01 and a 200-day simple moving average of $527.27.

Insider Activity

In related news, EVP Robert Desantis sold 376 shares of Intuitive Surgical stock in a transaction that occurred on Friday, November 29th. The shares were sold at an average price of $539.00, for a total value of $202,664.00. Following the completion of the sale, the executive vice president now owns 5,506 shares in the company, valued at approximately $2,967,734. This trade represents a 6.39 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, CFO Jamie Samath sold 188 shares of the company’s stock in a transaction on Friday, November 29th. The stock was sold at an average price of $539.00, for a total value of $101,332.00. Following the transaction, the chief financial officer now owns 8,757 shares in the company, valued at $4,720,023. This trade represents a 2.10 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold a total of 6,240 shares of company stock valued at $3,529,040 in the last quarter. Insiders own 0.80% of the company’s stock.

Institutional Investors Weigh In On Intuitive Surgical

A number of institutional investors have recently modified their holdings of ISRG. Atala Financial Inc acquired a new position in Intuitive Surgical in the 4th quarter valued at about $25,000. Hurley Capital LLC purchased a new position in shares of Intuitive Surgical in the fourth quarter valued at approximately $28,000. Berbice Capital Management LLC acquired a new position in shares of Intuitive Surgical in the fourth quarter valued at approximately $26,000. Parvin Asset Management LLC purchased a new stake in Intuitive Surgical during the 4th quarter worth approximately $26,000. Finally, BankPlus Trust Department purchased a new stake in Intuitive Surgical during the 4th quarter worth approximately $28,000. 83.64% of the stock is owned by institutional investors and hedge funds.

About Intuitive Surgical

Intuitive Surgical, Inc develops, manufactures, and markets products that enable physicians and healthcare providers to enhance the quality of and access to minimally invasive care in the United States and internationally. The company offers the da Vinci Surgical System that enables complex surgery using a minimally invasive approach; and Ion endoluminal system, which extends its commercial offerings beyond surgery into diagnostic procedures enabling minimally invasive biopsies in the lung.